The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease

International Journal of COPD

Volumn 3, Issue 4, 2008, Pages 659-669

  Hooper, C ^a   Calvert, James ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Carbocisteine; Chronic obstructive pulmonary disease (COPD); Exacerbation; Free radicals; Inflammation; Mucolytic; Oxidative stress; S carboxymethylcysteine

Indexed keywords

CARBOCISTEINE; CORTICOSTEROID; INTERLEUKIN 8; PLACEBO;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG TARGETING; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; SPUTUM VISCOSITY; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARBOCYSTEINE; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; EXPECTORANTS; FREE RADICAL SCAVENGERS; HUMANS; OXIDATIVE STRESS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 60249098194     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Adler KB, Holden-Stauffer WJ, Repine JE. 1990. Oxygen metabolites stimulate release of high molecular weight glycoconjugates by cell and organ cultures of rodent respiratory epithelium via an arachidonic acid - dependent mechanism. J Clin Invest, 85:75-85.
2. Allegra L, Cordaro C, Grassi C. 1996. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: A multicentre, double-blind, placebo-controlled trial. Respiration, 63:174-80.
3. Asti C, Melillo G, Caselli G F, et al. 1995. Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyper-responsiveness, Pharmacol Res, 31:387-92.
4. Aylward M. 1973. A between-patient, double-blind comparison of S-carboxymethylcysteine and bromhexine in chronic obstructive bronchitis. Curr Med Res Opin, 1:219-27.
5. Aylward M. 1974. An assessment of S-carboxymethyl-cysteine in the treatment of chronic bronchitis. Curr Med Res Opin, 2:387-94.
6. Barreiro E, Gea J, Corominas JM, et al. 2003. Nitric oxide synthases and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 29:771-8.
7. Barreiro E, de la PB, Minguella J, Corominas JM, et al. 2005. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 171:1116-24.
8. Braga PC, Borsa M, De Anglis L, et al. 1982. Pharmacokinetic behaviour of S-carboxymethyl-cysteine-lys in patients with chronic bronchitis. Clin Ther, 4:480-8.
9. Braga PC, Scaglione F, Scarpazza G, et al. 1985. Comparison between penetration of amoxicillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int J Clin Pharm Res, 5:331-40.
10. Braga PC, Allegra L, Bossi R, et al. 1989. Identification of subpopulations of bronchitic patients for suitable therapy by a dynamic rheological test. Int J Clin Pharm Res, 9:175-82.
11. Braga PC, Allegra L, Rampoldi C, et al. 1990. Long-lasting effects on rheology and clearance of bronchial mucus after short term administration of high doses of carbocysteine lysine to patients with chronic bronchitis. Respiration, 57:353-8.
12. Brandolini L, Allegretti M, Berdini V, et al. 2003. Carbocysteine lysine salt monohydrate (SCMC-Lys) is a selective scavenger of reactive oxygen intermediates (ROIs). Eur Cytokine Netw, 14:20-6.
13. Cakan G, Turkoz M, Turan T, et al. 2003. S-carboxymethylcysteine inhibits the attachment of streptococcus pneumoniae to human pharyngeal epithelial cells. Microbial pathogenesis, 34:261-5.
14. Carpagnano GE, Rests O, Foschino-Barbaro MP, et al. 2004. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol, 505:169-75.
15. Cheung D, Bel EF, Hartigh JD, et al. 1992. The effect of an inhaled neutral endopeptidase inhibitor, thiorphan on airway responses to neurokinin A in normal human in vivo. Am Rev Respir Dis, 145:1275-80.
16. Cheung D, Timmers MC, Zwinderman AH, et al. 1993. Neural endopepidase activity and airway hyperreponsiveness to neurokinin A in asthmatic subjects in vivo. Am Rev Respir Dis, 148:1467-73.
17. 1- secretion by the mucoactive drug S-carboxymethylcysteine lysine - salt in the isolated rabbit trachea. Eur Resp J, 7:1622-8.
18. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. 2005. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (BRONCHUS): a randomized placebo controlled trial. Lancet, 365:1552-60.
19. DeForge LE, Fantone JC, Kenny JS, et al. 1992. Oxygen radical scavengers selectively inhibit interleukin 8 activity in human whole blood. J Clin Invest, 90:2123-9.
20. Donaldson GC, Seemungal TAR, Bhowmik A, et al. 2002. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 57:847-52.
21. Edwards GF, Steel AE, Scott JK, et al. 1976. S-carboxy-methyl-cysteine in the humidification of sputum and treatment of chronic airways disease. Chest, 70:505-13.
22. Feldman C, Anderson R, Kanthakumar K, et al. 1994. Oxidant mediated ciliary dysfunction. Free Radic Biol Med, 17:1-10.
23. Goodman RM, Yergin BM, Sackner MA. 1978. Effects of S-carboxymethlycysteine on Tracheal Mucus Velocity. Chest, 74:615-8.
24. Grandjean EM, Berthet PH, Ruffman R, et al. 2000. Cost effectiveness analysis of N-acetylcysteine in chronic bronchopulmonary disease. Clin Ther, 22:209-20.
25. Grillage M, Barnard-Jones K. 1985. Long term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. The Br J Clin Pract, 39:395-8.
26. Havez R, Degand P, Roussel P, et al. 1977. Biochemical mechanism of action of cysteine derivatives on bronchial mucus. Poumon Coeur, 26:81-90.
27. Ischiura Y, Fujimura M, Yamamori C, et al. 2003. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. Br J Clin Pharmacol, 55:504-10.
28. 2-exposed rats. Nihon Kokyuki Gakkai Zasshi, 39:17-23.
29. Katayama N, Fujimura M, Ueda A, et al. 2001. Effects of carbocysteine on antigen-induced increases in cough sensitivity and bronchial responsiveness in guinea pigs. J Pharmacol Exp Ther, 297:975-80.
30. Kohler D, Siebold A, Daikeler G. 1982. The influence of carbocysteine on mucociliary clearance. Atamweg - Lungenkrankankh, 8: 201-4.
31. Lamblin A, Humbert P, Degand P, et al. 1977. Heterogenicity of the sugar side chains of bronchial mucins isolated from two subjects with chronic bronchitis. Clin Chim Acta, 79:425-36.
32. Montuschi P, Collins JV, Ciabattoni G, et al. 2000. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med, 162:1175-7.
33. Moretti M, Bottrighi P, Dallari R, et al. 2004. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the equalife study. Drugs Exp Clin Res, 30:143-52.
34. Ottenheijm CAC, Heunks LMA, Dekhuijzen RPN. 2008. Diaphragm adaptations in patients with COPD. Respir Res, 9:12.
35. Pinamonti S, Venturoli L, Leis M, et al. 2001. Antioxidant activity of carbocysteine lysine salt monohydrate. Panminerva Med, 43:215-20.
36. Poole PJ, Black PN. 2006. Mucolytic agents for chronic bronchitis or COPD. Cochrane Database of systematic reviews, Issue 3. Art No: CD001287.
37. Puchelle E, Girard F, Zahm ZM, 1976. Rheology of bronchial secretions and mucociliary transport. Bull Physiopathol Respir, 12:771-9.
38. Puchelle E, Aug F, Polu JM, 1978. Effect of the mucoregulator s-carboxymethyl-cysteine in patients with chronic bronchitis. Eur J Clin Pharmacol, 14:177-84.
39. Repine JE. 1997. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 156:341-57.
40. Riise GC, Larsson S, Lofdahl CG, et al. 1994. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur Respir J, 7:1673-7.
41. Seemungal TAR, Donaldson GC, Paul EA, et al. 1998. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med, 157:418-22.
42. Seemungal TAR, Donaldson GC, Bhowmik A, et al. 2000. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 161:1608-13.
43. Servin A, Garcet S, Huyen N, et al. 1976. Comparative pharmacokinetics of L-cysteine and one of its S-substituted derivatives, S-carboxymethyl-cysteine. J Pharmacol (Paris), 7:275-86.
44. Soler N, Ewig S, Torres A, et al. 1999. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J, 14:1015-22.
45. Steventon GB, Mitchell SC. 2005. Thiodiglycolic acid and dermatological reactions following S-carboxymethyl-1-cysteine administration. Br J Dermatol, 154:386-7.
46. Steventon GB, Mitchell SC. 2006. The sulphoxidation of S-carboxymethyl-1-cysteine in COPD. Eur Resp J, 27:865-6.
47. Swallow EB, Reyes D, Hopkinson NS, et al. 2007. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax, 62:115-20.
48. Tatsumi K. 2007. Carbocysteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc, 55:1884-87.
49. Thompson ML, Pavia D, Jones CJ, et al. 1975. No demonstrable effect of S-carboxymethyl-cysteine on clearance of secretions from the human lung. Thorax, 30:669-73.
50. Waring RH. 1988. Pharmacogenetics of the S-oxidation of S-carboxymethyl-L-cysteine. Drug Metabol Drug Interact, 6:253-63.
51. Yasuda H, Yamaya M, Sasaki T, et al. 2006. Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc, 54:378-80.
52. Zalacain R, Sobradillo V, Amilibia J et al. 1999. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J, 13:343-8.
53. Zheng CH, Ahmed K, Rikitomi N, et al. 1999. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol, 43:107-13.
54. Zheng JP, Kang J, Huang SG et al. 2008. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet, 371:2013-8.